You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
AstraZeneca
Mallinckrodt
Medtronic

Last Updated: February 22, 2024

IZERVAY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Izervay, and what generic alternatives are available?

Izervay is a drug marketed by Iveric Bio and is included in one NDA. There are eight patents protecting this drug.

This drug has ninety-eight patent family members in twenty-seven countries.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Izervay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 14, 2025. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for IZERVAY
International Patents:98
US Patents:8
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for IZERVAY
What excipients (inactive ingredients) are in IZERVAY?IZERVAY excipients list
DailyMed Link:IZERVAY at DailyMed
Drug patent expirations by year for IZERVAY
Drug Prices for IZERVAY

See drug prices for IZERVAY

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for IZERVAY
Generic Entry Date for IZERVAY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVITREAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for IZERVAY
Drug ClassComplement Inhibitor
Mechanism of ActionComplement Inhibitors

US Patents and Regulatory Information for IZERVAY

IZERVAY is protected by eight US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of IZERVAY is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting IZERVAY


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Iveric Bio IZERVAY avacincaptad pegol sodium SOLUTION;INTRAVITREAL 217225-001 Aug 4, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Iveric Bio IZERVAY avacincaptad pegol sodium SOLUTION;INTRAVITREAL 217225-001 Aug 4, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Iveric Bio IZERVAY avacincaptad pegol sodium SOLUTION;INTRAVITREAL 217225-001 Aug 4, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Iveric Bio IZERVAY avacincaptad pegol sodium SOLUTION;INTRAVITREAL 217225-001 Aug 4, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for IZERVAY

When does loss-of-exclusivity occur for IZERVAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06214437
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0607002
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 97889
Estimated Expiration: ⤷  Try a Trial

Patent: 97900
Estimated Expiration: ⤷  Try a Trial

Patent: 92874
Estimated Expiration: ⤷  Try a Trial

Patent: 24030
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1155822
Estimated Expiration: ⤷  Try a Trial

Patent: 3352037
Estimated Expiration: ⤷  Try a Trial

Patent: 4404046
Estimated Expiration: ⤷  Try a Trial

Patent: 8148840
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IZERVAY around the world.

Country Patent Number Title Estimated Expiration
Portugal 2860251 ⤷  Try a Trial
Brazil PI0607002 aptámeros terapêuticos úteis no tratamento de desordens relacionadas a complemento ⤷  Try a Trial
Israel 185312 אפטאמרים הנקשרים ל-5c המוצמדים לפוליאטילן גליקול (Polyethylene glycol conjugated c5 binding aptamers) ⤷  Try a Trial
Japan 2022153570 眼科症状を処置するまたは予防するための方法 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.